Valbiotis SA (EPA:VALDS)

Market Cap	20.84M +44.2%
Revenue (ttm)	905.00K +414.2%
Net Income	-9.42M
EPS	-0.47
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	375,872
Open	0.0012
Previous Close	n/a
Day's Range	n/a
52-Week Range	0.0001 - 0.0099
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 12, 2026

About Valbiotis

Valbiotis SA engages in the research and development of dietary supplements to prevent metabolic and cardiovascular diseases in France and Asia. The company offers supplements for immunity and vitality, health and wellbeing, metabolic and cardiovascular health, and beauty and physical comfort. It also develops TOTUM-63 for the reduction of fasting blood glucose and treatment of type 2 diabetes; TOTUM-854, which is in Phase II/III clinical trials for reducing systolic blood pressure; and TOTUM-448 for the reduction of hepatic steatosis. Addition...

• Industry: Pharmaceutical Preparations
• Founded: 2014
• Employees: 50
• Stock Exchange: Euronext Paris
• Ticker Symbol: VALDS

Financial Performance

In 2025, Valbiotis's revenue was 905,000, an increase of 414.20% compared to the previous year's 176,000. Losses were -9.42 million, -6.06% less than in 2024.

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Data Sources Report a data error